NCT03462212 - Carboplatin-Paclitaxel-Bevacizumab vs Carbo-Pacli-Beva-Rucaparib vs Carbo-Pacli-Ruca, Selected According to HRD Status, in Patients With Advanced Ovarian, Primary Peritoneal and Fallopian Tube Cancer, Preceded by a Phase I Dose Escalation Study on Ruca-Beva Combination | Biotech Hunter

Enrollment

290

Participants

Timeline

Start Date

March 17, 2021

Primary Completion Date

March 1, 2025

Study Completion Date

March 1, 2025

Conditions

Advanced (Stage IIIB-C-IV) Ovarian, Primary Peritoneal and Fallopian Tube Cancer

Interventions

DRUG

Carboplatin

chemotherapy medication

DRUG

Paclitaxel

chemotherapy medication

DRUG

Bevacizumab

Angiogenesis inhibitor

DRUG

Rucaparib

PARP inhibitor

Trial Locations (7)

RECRUITING

Ospedale Mater Salutis, Legnago

RECRUITING

ASST Grande Ospedale Metropolitano Niguarda, Milan

RECRUITING

Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Naples

RECRUITING

Azienda Ospedaliera di Perugia, Perugia

RECRUITING

Nuovo Ospedale degli Infermi, Ponderano

RECRUITING

Istituto di Candiolo - Fondazione del Piemonte per l'Oncologia - IRCCS, Turin

RECRUITING

Fondazione Policlinico Universitario A.Gemelli IRCCS, Rome